![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Court Upholds Shire Patent in Infringement Case Against Actavis
Court Upholds Shire Patent in Infringement Case Against Actavis
![GavelwithBaseBW.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/GavelwithBaseBW.gif?t=1579650370&width=430)
Actavis received a setback in its quest to market a generic version of Lialda following a district court’s decision upholding Shire’s patent covering the ulcerative colitis drug.
Judge Donald Middlebrooks of the U.S. District Court for Southern Florida wrote that Actavis — formerly known as Watson at the start of litigation — infringed two claims of Shire’s ’720 patent, which expires June 8, 2020.
Shire contended the generic version infringed the patent because it featured a tablet structure with a water-resistant material and a more readily dissolved component, which work to delay the release of the active ingredient.
Upcoming Events
-
21Oct